Citations

Clear

56 citation(s) found for "Mathai, S C".

Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease
Shah, Sanjiv J. , Borlaug, Barry A. , Leary, Peter J. , Patel, Harnish, Kelemen, Benjamin W., Houston, Brian A. , Damico, Rachel L. , Mathai, Stephen C. , Kasper, Edward K. , Tampakakis, Emmanouil, Patel, Harnish H, Miller, Wayne L. , Kolb, Todd M. , Damico, Rachel, Kass, David A. , Borlaug, Barry A , Leary, Peter J , Shah, Sanjiv J , Tampakakis, Emmanouil , Hassoun, Paul M. , Tedford, Ryan J. , Mathai, Stephen C

Mayo Clinic

Circulation: Heart Failure | April 11, 2018 | Volume: 11 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.117.004436 | PMID 29643065 Get It

Background: Patients with combined post- and precapillary pulmonary hypertension due to left heart disease have a worse prognosis compared with isolated postcapillary. However, it remains unclear whether increased mortality in combined post- and precapillary pulmonary hypertension is simply a result of higher total right ventricular load. Pulmonary effective arterial elastance (Ea) is a measure of total right ventricular afterload, reflecting both resistive and pulsatile components. We aimed to test whether pulmonary Ea discriminates survivors from nonsurvivors in patients with pulmonary hypertension due to left heart disease and if it does so better than other hemodynamic parameters associated with combined post- and precapillary pulmonary hypertension. Methods and Results: We combined 3 large heart failure patient cohorts (n=1036) from academic hospitals, including patients with pulmonary hypertension due to heart failure with preserved ejection fraction (n=232), reduced ejection fraction (n=335), and a mixed population (n=469). In unadjusted and 2 adjusted models, pulmonary Ea more robustly predicted mortality than pulmonary vascular resistance and the transpulmonary gradient. Along with pulmonary arterial compliance, pulmonary Ea remained predictive of survival in patients with normal pulmonary vascular resistance. The diastolic pulmonary gradient did not predict mortality. In addition, in a subset of patients with echocardiographic data, Ea and pulmonary arterial compliance were better discriminators of right ventricular dysfunction than the other parameters. Conclusions: Pulmonary Ea and pulmonary arterial compliance more consistently predicted mortality than pulmonary vascular resistance or transpulmonary gradient across a spectrum of left heart disease with pulmonary hypertension, including patients with heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, and pulmonary hypertension with a normal pulmonary vascular resistance.
Enhancing Insights into Pulmonary Vascular Disease Through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report
Newman, John H. , Rich, Stuart , Alexander, John H. , Beck, Gerald J. , Benza, Raymond L. , Bull, Todd M., Chun, Hyung J. , Doogan, Declan, Dupuis, Jocelyn , Erzurum, Serpil C. , Frantz, Robert P. , Geraci, Mark W. , Gillies, Hunter , Gladwin, Mark T. , Gray, Michael P. , Hill, Nicholas S. , Hunter, Kendall S. , Jing, Zhi‐Cheng , Johns, Roger A. , Kaul, Sanjay , Lahm, Tim , Lewis, Greg , Mathai, Stephen C. , McLaughlin, Vallerie V. , Michelakis, Evangelos D. , Nathan, Steven D. , Nichols, William C. , Page, Grier P. , Rabinovitch, Marlene , Rich, Jonathan D. , Rischard, Franz , Rounds, Sharon , Shah, Sanjiv J. , Tapson, Victor F. , Lowy, Naomi, Stockbridge, Norman, Weinmann, Gail, Xiao, Lei , Xiao, Lei , Abman, Steven H. , Barnard, John , Benza, Raymond L. , Chan, Stephen Y. , Hemnes, Anna R. , Herbst, Roy S. , Hernandez, Adrian F. , Horn, Evelyn M. , Kawut, Steven M. , Leopold, Jane A. , McLaughlin, Vallerie V. , Shah, Sanjiv J , Frantz, Robert P , Rischard, Franz P , Mathai, Stephen C

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 21, 2017 | Volume: 195 | Issue: 12 | Pages: 1661-1670

10.1164/rccm.201701-0150ws | PMID 28430547 Get It

Abstract The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched “Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics” (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.
An Observational Study of Inhaled‐Treprostinil Respiratory‐Related Safety in Patients with Pulmonary Arterial Hypertension
Zamanian, Roham T. , Levine, Deborah J. , Souza, Samuel Amorim de, Rosenzweig, Erika B. , Alnuaimat, Hassan, Mathai, Stephen C. , Leedom, Nicole, DeAngelis, Kiernan , Lim, Allison , Marco, Teresa De , Bourge, Robert C. , Burger, Charles D. , Rosenzweig, Erika B , Mathai, Stephen C

Mayo Clinic

Pulmonary Circulation | June 17, 2016 | Volume: 6 | Issue: 3 | Pages: 329-337

10.1086/688059 | PMID 27683610 Get It

Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory‐related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to characterize respiratory‐related adverse events (AEs) associated with current or recent treatment with inhaled treprostinil and to compare the incidence of respiratory‐related AEs in PAH patients treated with inhaled treprostinil with that in patients treated with other Food and Drug Administration (FDA)–approved PAH therapies. This was a long‐term, prospective, observational study. All respiratory‐related AEs were recorded during the study. The number of PAH patients enrolled was 1,333, 666 treated with inhaled treprostinil and 667 controls (treated with an FDA‐approved PAH therapy other than inhaled treprostinil), for a total of 958 and 1,094 patient‐years of exposure, respectively. In the inhaled‐treprostinil group, 1,281 respiratory‐related AEs were reported in 403 patients (61%), and in the control group, 1,295 respiratory‐related AEs were reported in 388 patients (58%). Cough, throat irritation, nasal discomfort, and hemoptysis were the most common respiratory‐related AEs (occurring in ≥2% of patients in either treatment group) that demonstrated a higher number of events per patient‐year of exposure in the inhaled‐treprostinil group than in the control group (risk ratio [95% confidence interval]: 1.487 [1.172–1.887], 3.777 [2.050–6.956], 2.039 [1.072–3.879], and 1.957 [1.024–3.741], respectively). Overall, inhaled treprostinil was well tolerated by PAH patients in routine clinical care, with respiratory‐related AEs consistent with the known safety profile (trial registration: clinicaltrials.gov identifier: NCT01266265).
Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
Tedford, Ryan J. , Mathai, Stephen C. , Girgis, Reda E. , Thiemann, David R. , Cingolani, Oscar H. , Mudd, James O., Redfield, Margaret M. , Lederer, David J. , Hassoun, Paul M. , Russell, Stuart D. , Borlaug, Barry A. , Kass, David A. , Lederer, David J , Tedford, Ryan J , Mathai, Stephen C

Mayo Clinic

Circulation | December 2, 2011 | Volume: 125 | Issue: 2 | Pages: 289-297

10.1161/circulationaha.111.051540 | PMID 22131357 Get It

Background— Right ventricular failure from increased pulmonary vascular loading is a major cause of morbidity and mortality, yet its modulation by disease remains poorly understood. We tested the hypotheses that, unlike the systemic circulation, pulmonary vascular resistance (R PA ) and compliance (C PA ) are consistently and inversely related regardless of age, pulmonary hypertension, or interstitial fibrosis and that this relation may be changed by elevated pulmonary capillary wedge pressure, augmenting right ventricular pulsatile load. Methods and Results— Several large clinical databases with right heart/pulmonary catheterization data were analyzed to determine the R PA -C PA relationship with pulmonary hypertension, pulmonary fibrosis, patient age, and varying pulmonary capillary wedge pressure. Patients with suspected or documented pulmonary hypertension (n=1009) and normal pulmonary capillary wedge pressure displayed a consistent R PA -C PA hyperbolic (inverse) dependence, C PA =0.564/(0.047+R PA ), with a near-constant resistance-compliance product (0.48±0.17 seconds). In the same patients, the systemic resistance-compliance product was highly variable. Severe pulmonary fibrosis (n=89) did not change the R PA -C PA relation. Increasing patient age led to a very small but statistically significant change in the relation. However, elevation of the pulmonary capillary wedge pressure (n=8142) had a larger impact, significantly lowering C PA for any R PA and negatively correlating with the resistance-compliance product ( P <0.0001). Conclusions— Pulmonary hypertension and pulmonary fibrosis do not significantly change the hyperbolic dependence between R PA and C PA , and patient age has only minimal effects. This fixed relationship helps explain the difficulty of reducing total right ventricular afterload by therapies that have a modest impact on mean R PA . Higher pulmonary capillary wedge pressure appears to enhance net right ventricular afterload by elevating pulsatile, relative to resistive, load and may contribute to right ventricular dysfunction.